Deal Making

Featured on Deal Making

Lilly going bigger on obesity with Versanis buy
Deal-Making
Lilly going bigger on obesity with Versanis buyLilly going bigger on obesity with Versanis buy

Eli Lilly will pay up to $1.925 billion to acquire biotech Versanis, adding its Phase II obesity candidate bimagrumab to its pipeline.

byDan Stanton
Jul 17, 2023
|
2 Min Read
MilliporeSigma invests $25m to expand cell culture media production
Deal-Making
MilliporeSigma invests $25m to expand cell culture media productionMilliporeSigma invests $25m to expand cell culture media production
byMillie Nelson
Jul 14, 2023
2 Min Read
Ardena and RiboPro ink RNA deal
Deal-Making
Ardena and RiboPro ink RNA dealArdena and RiboPro ink RNA deal
byMillie Nelson
Jul 11, 2023
2 Min Read
Thermo Fisher to add data platform with $913m CorEvitas buy
Deal-Making
Thermo Fisher to add data platform with $913m CorEvitas buyThermo Fisher to add data platform with $913m CorEvitas buy
byMillie Nelson
Jul 10, 2023
2 Min Read
Just-Evotec awarded $74m DOD mAb contract
Deal-Making
Just-Evotec awarded $74m DOD mAb contractJust-Evotec awarded $74m DOD mAb contract
byMillie Nelson
Jul 7, 2023
2 Min Read
Donaldson expands portfolio with $148m Univercells buy
Deal-Making
Donaldson expands portfolio with $148m Univercells buyDonaldson expands portfolio with $148m Univercells buy
byMillie Nelson
Jul 4, 2023
3 Min Read

More from Deal Making

Lilly boosts diabetes portfolio with Sigilon buy
Deal-Making
Lilly boosts diabetes portfolio with Sigilon buy
Lilly boosts diabetes portfolio with Sigilon buy
Jun 30, 2023
|
2 Min Read
byMillie Nelson
Wood wins $50m GSK deal to sustain specialized meds manufacturing
Deal-Making
Wood wins $50m GSK deal to sustain specialized meds manufacturing
Wood wins $50m GSK deal to sustain specialized meds manufacturing
Jun 29, 2023
|
2 Min Read
byMillie Nelson
Curia signs cell line deal with MilliporeSigma
Deal-Making
Curia signs cell line deal with MilliporeSigma
Curia signs cell line deal with MilliporeSigma
Jun 27, 2023
|
1 Min Read
byMillie Nelson
Verismo and UPenn ink cell therapy manufacturing deal
Deal-Making
Verismo and UPenn ink cell therapy manufacturing deal
Verismo and UPenn ink cell therapy manufacturing deal
Jun 26, 2023
|
2 Min Read
byMillie Nelson
Coherus picking up oncology antibodies in Surface acquisition
Deal-Making
Coherus picking up oncology antibodies in Surface acquisition
Coherus picking up oncology antibodies in Surface acquisition
Jun 16, 2023
|
2 Min Read
byDan Stanton
Novartis bolstering renal pipeline in $3.2bn Chinook buy
Deal-Making
Novartis bolstering renal pipeline in $3.2bn Chinook buy
Novartis bolstering renal pipeline in $3.2bn Chinook buy
Jun 12, 2023
|
1 Min Read
byBPI Staff
Pfizer inks $411m biosimilar contract in busy week for Samsung Bio
Deal-Making
Pfizer inks $411m biosimilar contract in busy week for Samsung Bio
Pfizer inks $411m biosimilar contract in busy week for Samsung Bio
Jun 9, 2023
|
2 Min Read
byDan Stanton
BIO 2023: Bringing CDMOs together
Bioprocess Insider
BIO 2023: Bringing CDMOs together
BIO 2023: Bringing CDMOs together
Jun 5, 2023
|
2 Min Read
byDan Stanton
Rentschler teams with Ikarovec to scale-up AAV development in UK
Deal-Making
Rentschler teams with Ikarovec to scale-up AAV development in UK
Rentschler teams with Ikarovec to scale-up AAV development in UK
Jun 5, 2023
|
2 Min Read
byMillie Nelson
Getinge forks out $120m to buy single-use solutions firm HPNE
Deal-Making
Getinge forks out $120m to buy single-use solutions firm HPNE
Getinge forks out $120m to buy single-use solutions firm HPNE
Jun 2, 2023
|
2 Min Read
byMillie Nelson
Lonza lays out $100m+ for ADC firm Synaffix
Deal-Making
Lonza lays out $100m+ for ADC firm Synaffix
Lonza lays out $100m+ for ADC firm Synaffix
Jun 2, 2023
|
2 Min Read
byDan Stanton
Pfizer expands Epogen biosimilar deal with German CDMO
Deal-Making
Pfizer expands Epogen biosimilar deal with German CDMO
Pfizer expands Epogen biosimilar deal with German CDMO
May 25, 2023
|
2 Min Read
byDan Stanton
AstraZeneca ups gene editing capabilities with Revvity deal
Deal-Making
AstraZeneca ups gene editing capabilities with Revvity deal
AstraZeneca ups gene editing capabilities with Revvity deal
May 22, 2023
|
2 Min Read
byMillie Nelson
Thermo Fisher eyes up to $50bn M&A in coming years
Deal-Making
Thermo Fisher eyes up to $50bn M&A in coming years
Thermo Fisher eyes up to $50bn M&A in coming years
May 19, 2023
|
3 Min Read
byDan Stanton
uBriGene steps into US with Mustang Bio facility buy
Deal-Making
uBriGene steps into US with Mustang Bio facility buy
uBriGene steps into US with Mustang Bio facility buy
May 19, 2023
|
2 Min Read
byMillie Nelson
Scribe and Prevail ink $75m CRISPR deal
Deal-Making
Scribe and Prevail ink $75m CRISPR deal
Scribe and Prevail ink $75m CRISPR deal
May 18, 2023
|
2 Min Read
byMillie Nelson
Astellas and Sony ink deal to develop ADC platform
Deal-Making
Astellas and Sony ink deal to develop ADC platform
Astellas and Sony ink deal to develop ADC platform
May 17, 2023
|
1 Min Read
byMillie Nelson
Recipharm biologics biz signs mRNA deal with MIT
Deal-Making
Recipharm biologics biz signs mRNA deal with MIT
Recipharm biologics biz signs mRNA deal with MIT
May 15, 2023
|
2 Min Read
byMillie Nelson
Waters hopes for bioanalytic windfall after $1.36bn deal bring light scattering
Deal-Making
Waters hopes for bioanalytic windfall after $1.36bn deal bring light scattering
Waters hopes for bioanalytic windfall after $1.36bn deal bring light scattering
May 12, 2023
|
2 Min Read
byDan Stanton
Sandoz signs biosimilar pact with Just-Evotec
Deal-Making
Sandoz signs biosimilar pact with Just-Evotec
Sandoz signs biosimilar pact with Just-Evotec
May 10, 2023
|
2 Min Read
byDan Stanton
Baxter sells biopharma services business to PE for $4.25bn
Deal-Making
Baxter sells biopharma services business to PE for $4.25bn
Baxter sells biopharma services business to PE for $4.25bn
May 9, 2023
|
1 Min Read
byDan Stanton
Ginkgo and Boehringer partner to develop therapeutic molecules
Deal-Making
Ginkgo and Boehringer partner to develop therapeutic molecules
Ginkgo and Boehringer partner to develop therapeutic molecules
May 8, 2023
|
2 Min Read
byMillie Nelson
J&J forks out $245m to develop CAR-T therapies
Deal-Making
J&J forks out $245m to develop CAR-T therapies
J&J forks out $245m to develop CAR-T therapies
May 4, 2023
|
2 Min Read
byMillie Nelson
BioCina awarded $3.3m grant to bolster mRNA capabilities
Deal-Making
BioCina awarded $3.3m grant to bolster mRNA capabilities
BioCina awarded $3.3m grant to bolster mRNA capabilities
May 4, 2023
|
2 Min Read
byMillie Nelson
Astellas forks out $5.9bn to buy Iveric Bio
Deal-Making
Astellas forks out $5.9bn to buy Iveric Bio
Astellas forks out $5.9bn to buy Iveric Bio
May 3, 2023
|
2 Min Read
byMillie Nelson
Plasticell and LambdaGen team on off-the-shelf stem cell platform
Deal-Making
Plasticell and LambdaGen team on off-the-shelf stem cell platform
Plasticell and LambdaGen team on off-the-shelf stem cell platform
Apr 28, 2023
|
2 Min Read
byAnna Brown
Serum Institute to inject another $150m into Biocon
Deal-Making
Serum Institute to inject another $150m into Biocon
Serum Institute to inject another $150m into Biocon
Apr 27, 2023
|
1 Min Read
byMillie Nelson
Danaher reportedly drops Catalent courtship, but is CDMO acquisition imminent?
Deal-Making
Danaher reportedly drops Catalent courtship, but is CDMO acquisition imminent?
Danaher reportedly drops Catalent courtship, but is CDMO acquisition imminent?
Apr 19, 2023
|
2 Min Read
byDan Stanton
Merck to buy Prometheus for $10.8bn
Deal-Making
Merck to buy Prometheus for $10.8bn
Merck to buy Prometheus for $10.8bn
Apr 18, 2023
|
2 Min Read
byMillie Nelson
AnaBios bolsters cell portfolio with Cell Systems buy
Deal-Making
AnaBios bolsters cell portfolio with Cell Systems buy
AnaBios bolsters cell portfolio with Cell Systems buy
Apr 17, 2023
|
2 Min Read
byMillie Nelson

Webinars

Ask the Expert webcasts
ATE Webcasts
Register Now: Introducing Super Refined™ Poloxamer 188: Optimized for Mammalian Cell Culture with Exceptional Batch-to-Batch Consistency
Register Now: Introducing Super Refined™ Poloxamer 188: Optimized for Mammalian Cell Culture with Exceptional Batch-to-Batch Consistency
Ask the Expert webcasts
ATE Webcasts
Register Now: Introduction to Lonza CHO Media Portfolio: Harnessing Simplicity with the TheraPRO® CHO Media System
Register Now: Introduction to Lonza CHO Media Portfolio: Harnessing Simplicity with the TheraPRO® CHO Media System
Ask the Expert webcasts
ATE Webcasts
Register Now: Out of the Box Computer Software Assurance with ValGenesis VLMS
Register Now: Out of the Box Computer Software Assurance with ValGenesis VLMS
Insider News
See all
Dec 2 - Dec 5, 2024
The European Cell and Gene Therapy Congress for Groundbreaking Manufacturing, Commercialisation & Analytical Strategies: World renowned leaders share the latest process development, analytical and market access strategies to improve manufacturing scalability, quality and cost to propel your CGT programmes to commercial success
Learn More

Innovative Technology

Lonza WP
Sponsored Content
Exploring Technologies for cGMP Success with Encapsulation of Nucleic Acid-based Therapeutics
Exploring Technologies for cGMP Success with Encapsulation of Nucleic Acid-based Therapeutics

Oct 28, 2024

Repligen white paper
Sponsored Content
30% Increase in Concentration Accuracies with KrosFlo® RS 30 RPM™ TFF System
30% Increase in Concentration Accuracies with KrosFlo® RS 30 RPM™ TFF System

Oct 25, 2024

Solventum white paper
Sponsored Content
3M™ Harvest RC Centrate Chromatographic Clarifier: Evolving the Role of Clarification in the Biopharmaceutical Manufacturing Process
3M™ Harvest RC Centrate Chromatographic Clarifier: Evolving the Role of Clarification in the Biopharmaceutical Manufacturing Process

Oct 25, 2024